William Lazonick is professor of economics at University of Massachusetts Lowell. He is also visiting professor at University of Ljubljana, professeur associé at Institut Mines-Télécom in Paris, and professorial research associate, SOAS, University of London. He is co-founder and president of the Academic-Industry Research Network, a 501(c)(3) research organization. Previously, he was on the faculties of Harvard University, Columbia University, INSEAD, and University of Tokyo. His book Sustainable Prosperity in the New Economy? Business Organization and High-Tech Employment in the United States (Upjohn Institute 2009) won the 2010 Schumpeter Prize. His article “Profits Without Prosperity: Stock Buybacks Manipulate the Market and Leave Most Americans Worse Off,” earned the HBR McKinsey Award for outstanding article in Harvard Business Review in 2014. His most recent papers include “Stock Buybacks: From Retain-and-Reinvest to Downsize-and-Distribute”; “Innovative Enterprise or Sweatshop Economics? In Search of Foundations of Economic Analysis”; “U.S. Pharma’s Business Model: Why It Is Broken and How It Can Be Fixed” (see submissions #1 and #2 to the UN High-Level Panel on Access to Medicines); and “The Mismeasure of Mammon: The Uses and Abuses of Executive Pay Data.”.” His recent research has been funded by the Institute for New Economic Thinking, Ford Foundation, and European Commission. Lazonick has a BCom from University of Toronto, MSc in economics from London School of Economics, a PhD in economics from Harvard University, and an honorary doctorate from Uppsala University. In December 2016 Lazonick will receive an honorary doctorate from University of Ljubljana.

By this expert

Is the Most Unproductive Firm the Foundation of the Most Efficient Economy?

Article | Jan 31, 2020

How Penrosian Learning Confronts the Neoclassical Fallacy

Is the Most Unproductive Firm the Foundation of the Most Efficient Economy? Penrosian Learning Confronts the Neoclassical Fallacy

Paper Working Paper Series | | Jan 2020

To get beyond the neoclassical fallacy, economists have to stop relying on constrained-optimization methodology

Financialization of the U.S. Pharmaceutical Industry

Article | Dec 2, 2019

Pharmaceutical drugs are often a matter of life or death. It should be a prime objective of government policy to rid the industry of financialization.

Don't “Buyback” Fair Labor Standards

Article | Feb 20, 2019

We need to ban stock buybacks, while building a movement for basic economic rights

Featuring this expert

Hidden Costs Of Healthcare

Event Conference | Nov 15, 2019

Increased financialization is driving healthcare costs and must be addressed in our nation’s public policy.

After Over Three Decades, Rebel Economist Breaks Through to Washington. Here’s How He Did It.

Article | Jul 1, 2019

The idea that businesses are run to maximize profits for shareholders is just plain wrong, says William Lazonick

HuffPo Cites INET Stock Buyback Research

News Apr 19, 2019

The Huffington Post features INET research on stock buybacks

William Lazonick in the New York Times on Pharma CEO Pay

News Feb 26, 2019

INET grantee William Lazonick’s research on drug pricing is featured in a New York Times op-ed